Gynecologic cancer
Conditions
Interventions
Oral medication for 3 days (day 1: 125mg, day2-3 80mg)
Oral medication for 3 days(placebo)
Sponsors
Kyushu University Obstetrics gynecology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Patient of gynecologic cancer who received TC regimen as first line chemotherapy 2. Age: 20-80 years old 3. PS: 0-2 4. Patients who sign informed consent
Exclusion criteria
Exclusion criteria: 1.Patients with severe liver or renal dysfunction 2.Patients with nausea or vomiting before chemotherapy within 24 hours 3.Patients who received antiemetic drug before chemotherapy within 48 hours 4.Patients who continuously received anti-allergic drug or steroid 5.Patients with a current diagnosis that induced nausea or vomiting 6.Patients who received prior abdominal or pelvic radiotherapy 7.Patients with DM required continuous insulin therapy 8.Patients with pregnancy 9.Patients who judged that the doctor is inadequate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of hypersensitive reaction | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of the patient without vomiting Rate of the patient without significant nausea | — |
Countries
Japan
Contacts
Public ContactHideaki Yahata
Kyushu University Obstetrics gynecology
Outcome results
None listed